The HeartMate 3™ lvad and HeartMate ii™ LVAD: innovation, experience and improved outcomes

HeartMate LVADs have been both the innovators and leaders of left ventricular assist device (LVAD) therapy for decades: Beginning with the very first FDA approved HeartMate LVAD in 1994, to the proven success of the HeartMate II LVAD in 2008, and now today, the next milestone – the HeartMate 3 LVAD.

HeartMate LVADs are intended for certain advanced heart failure patients. They are designed to restore blood flow and improve survival, functional status and quality of life.1,2,3,4 LVADs are designed for different indications. Clinicians determine which device is best for each patient.

HeartMate 3™ lvad: a new milestone in lvad therapy

The HeartMate 3 LVAD received FDA approval in 2017 for short-term support (while waiting for a donor heart). The latest innovation in LVAD technology – the HeartMate 3 LVAD offers significant improvement in survival and quality of life5 with advanced innovations and design. This is due, in part, to its Full MagLevTM flow technology, which helps protect the blood as it flows through the pump.

Significant Improvement in Heart Failure Class1

New York Heart Association (NYHA) Classification is a common scale that doctors use to measure heart failure. Patients who received the HeartMate 3 LVAD had a significant improvement in their NYHA class—100 percent of patients prior to receiving the device were in NYHA Class IIIB or IV, which are considered more severe stages of heart failure. Six months after receiving the HeartMate 3 LVAD, 77 percent of patients improved to NYHA Class I or II, which are considered more mild stages of heart failure.

77%

of heartmate 3™ LVAD patients reversed the symptoms of their heart failure1

Meaningful Distance Increase in Six-Minute Walk Test6

The Six-Minute Walk Test is a common test doctors use to measure the ability to perform daily physical activities in patients with heart failure. Before receiving the HeartMate 3 LVAD, patients in the study were able to walk an average of 164 meters (about 180 yards) in six minutes. Six months after receiving the HeartMate 3 LVAD patients were able to walk an average of 296 meters (about 324 yards) in six minutes. That’s an 80 percent improvement in distance.

image description

HeartMate ii™ lvad: Proven Long-term results

To date, over 25,000 heart failure patients have received the HeartMate II LVAD7. Many have passed the 5-year milestone on therapy, with some still on therapy after 10-plus years. The HeartMate II LVAD was the first device approved by the FDA for Destination Therapy, sometimes called permanent support. Destination Therapy may be an option for people who are ineligible for a heart transplant. The HeartMate II LVAD is the most widely used and extensively studied LVAD in the world.8

OVER 25,000 heartmate ii™ lvad patients7
80%

of HeartMate™ II LVAD patients

reversed the symptoms of their heart failure3

HeartMate™ II LVAD patients are

 
7x

more likely to survive

compared to patients on medication treatment alone3,9

how is heart failure impacting your life?

take the short quiz

image description

heartmate™ LVADs are available nationwide

or call us at 1-855-7-HEARTMATE

Each of our heart failure patient stories reflects one person’s experience. Keep in mind that not everyone will experience the same results. Talk to your doctor about the benefits and risks of your treatment options. And please note that Abbott does not provide medical services or advice as part of this website. Click here for indication and risk information for the HeartMate IITM LVAD and the HeartMate 3™ LVAD.

References:

1.Mehra MR, Naka Y, Uriel N, et al; for the MOMENTUM 3 investigators. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med. 2017;376:440-450.  2 Cowger JA, Naka Y, Aaronson K, Horstmanshof D, Gulati S, Rinde-Hoffman D, et al (2017). Quality of life and functional capacity in the multicenter study of MAGLEV technology in patients undergoing mechanical circulatory support therapy with the HeartMate 3 (MOMENTUM 3) Pivotal Trial.  3. Park SJ, Milano C A, Tatooles A J, Rogers JG, Adamson R M, Steidley E., et al. for the HeartMate II Clinical Investigators. (2012). Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circulation: Heart Failure, 5(2), 241-248. http://dx.doi.org/10.1161/CIRCHEARTFAILURE.111.963991.  4. John R, Naka Y, Smedira NG, Starling R, Jorde U, Eckman P, et al (2011). Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. Annals of Thoracic Surgery, 92(4), 1406-1413.  5. Jorde, U. P., Kushwaha, S. S., Tatooles A. J., Naka, Y., Bhat, G., Long, J. W., et al (2014). Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device. A prospective study using the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). Journal of the American College of Cardiology, 63(17), 1751-1757.  6. HeartMate 3 LVAD Patient Handbook. Document 10002833.B. Published September 2015.  7. St. Jude Medical. Data on file, Report SJM-HM-1016_0032(1).  8. Abbott data on File. SJM-HM-0817-0090.  9. Rose EA, Gelijns AC, Moskowitz A J, et al; for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443.